The Joint Corp (JYNT) - Price-to-Projected Revenue Ratio
The Joint Corp. (JYNT) dominance in the affordable spinal therapy niche and licensing barriers ensure stable positioning, as confirmed by the forward price-to-sales valuation chart. The value of 1.00 marks a new level. A decentralized franchising network reduces operational risks, while the shift toward organic expansion instead of costly acquisitions strengthens liquidity, creating a foundation for stable performance growth.
The Joint - analytical breakdowns and key metrics (JYNT)
- stock price and consensus target price:
- market capitalization indicators:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Debt to Equity The Joint Corp.|JYNT - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio The Joint Corp.|JYNT - Company Cumulative Indebtedness|Debt to Book Value The Joint|JYNT - Company Long-Term Loans and Borrowings|Company Short-Term Debts The Joint Chiropractic|Quick Liquidity thejoint.com
- business earnings and investment ratios data:
JYNT - Company Net Income|Expected Profit The Joint Corp.|JYNT - Company Value to Net Income|Future Price to Earnings The Joint Corporation|JYNT - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio The Joint|JYNT - Operating income before deduction of amortization|Earnings per share for the last twelve months The Joint Chiropractic|JYNT - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months thejoint.com|JYNT - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year The Joint Corp.
- revenue and sales details:
General company analysis:The Joint Chiropractic (JYNT)
Investors use this ratio to assess the market value of a business relative to expected sales to determine if an asset is overbought during periods of stagnation. The ratio of market capitalization to projected revenue for The Joint Corp. (JYNT) reflects the resilience of the franchising model to costs, where licensing barriers and brand scale create a defensive moat, a fact clearly confirmed by the forward price-to-sales valuation trend.
Key competitors
HCA Healthcare - Forward Price-to-Revenue Multiple|Forward Price to Sales THC|FMS - Price-to-Projected Revenue Ratio|Solventum Health - Price to Expected Revenue Ratio|Encompass Health (EHC) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Universal Health Services, Inc. (UHS)|DVA (DaVita) - Forward P/S Multiple|RadNet Inc (RDNT) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Option Care Health Inc (OPCH)|Surgery Partners Group - Market Cap to Projected Revenue|Premier, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio EYE (nationalvision.com)|PGNY: Forward Price-to-Revenue Multiple|Forward Price to Sales ARDT (Ardent Health)|SEM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Astrana Corp|Price-to-Projected Revenue Ratio Pediatrix Corp|Market Cap to Future Revenue Ratio US Physical Therapy Inc USPH|Price-to-Projected Revenue Ratio The Pennant Group (PNTG)|ORGO (Organogenesis Holdings Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio Nutex Health Corp NUTX|AUNA (Auna Corp) - Future Price to Revenue|SBC: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio evolus.com EOLS|Community Health Systems, Inc. (CYH) - Price-to-Projected Revenue Ratio|SKIN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple MDWD|Market Cap to Future Revenue Ratio Biote Corporation BTMD|Price-to-Projected Revenue Ratio DocGo Inc. (DCGO)|p3hp.org - Market Cap to Projected Revenue|Gain Therapeutics - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio EUDA (EUDA Health Holdings)|BMGL: Forward Price-to-Revenue Multiple|CollPlant Biotechnologies - Price to Expected Revenue Ratio|Cuprina Holdings (Cayman) Ltd (CUPR) - Price-to-Projected Revenue Ratio|concordmedical.com - Forward Price to Sales|AMS (American Shared Hospital Services) - Forward P/S Multiple|Market Cap to Future Revenue Ratio MEDIROM Healthcare Group Inc. MRM|Forward P/S Multiple ALBT|Forward P/S Multiple DIH Group (DHAI)|Longevity Health Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NIVF (newgenivf.com)|ATIP - Price-to-Projected Revenue Ratio|CareMax Inc. (CMAX) - Forward Price-to-Revenue Multiple|KDLY: Forward P/S Multiple|Market Cap to Future Revenue Ratio ModivCare Corp (MODV)|Price-to-Projected Revenue Ratio Novo Integrated Sciences|Market Cap to Projected Revenue SSY (SunLink Health Systems, Inc)|Forward Price-to-Revenue Multiple BACK (IMAC Holdings)
